Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group

The leukotrienes are known to be important mediators of bronchial asthma. The ability of montelukast, a potent and selective CysLT1 leukotriene receptor antagonist, to cause a dose-related improvement in chronic asthma was investigated in a placebo-controlled, multicentre, parallel-group study. After a two week placebo run-in period, chronic asthmatic patients with a forced expiratory volume in one second (FEV1) 40-80% predicted with > or = 15% increase (absolute value) after beta2-agonist were randomly assigned to one of four treatment groups (placebo or montelukast 2, 10, or 50 mg once daily in the evening) for a three week, double-blind treatment period. For patient-reported end-points (daytime symptom score, use of as needed inhaled beta2 agonist, asthma-specific quality of life) and frequency of asthma exacerbations, montelukast 10 and 50 mg caused similar responses, superior to 2 mg and significantly (p<0.05; linear trend test) different from placebo. All three doses caused improvements in FEV1 and morning and evening peak expiratory flow rate (PEFR) that were significantly (p<0.05) different from placebo. Differences (least square mean) between the pooled 10 and 50 mg montelukast treatment groups and placebo were: 7.1% change from baseline in FEV1, 19.23 L x min(-1) in morning PEFR, -0.29 in daytime asthma symptom score (absolute value), and -0.82 in beta2-agonist use (puff x day(-1)). The incidence of adverse experiences was neither dose-related nor different between montelukast and placebo treatments. We conclude that montelukast causes a dose-related improvement in patient-reported asthma end-points over the range 2-50 mg. Montelukast causes benefit to chronic asthmatic patients by improving asthma control end-points.

This article has been cited by other articles:

				H. K. Reddel, D. R. Taylor, E. D. Bateman, L.-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, et al. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 59 - 99. [Abstract] [Full Text] [PDF]

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				V. Kumar, P. Ramesh, R. Lodha, R. M. Pandey, and S. K. Kabra Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial J Trop Pediatr, October 1, 2007; 53(5): 325 - 330. [Abstract] [Full Text] [PDF]

				E. Migoya, G. L. Kearns, A. Hartford, J. Zhao, J. van Adelsberg, C. A. Tozzi, B. Knorr, and P. Deutsch Pharmacokinetics of Montelukast in Asthmatic Patients 6 to 24 Months Old J. Clin. Pharmacol., May 1, 2004; 44(5): 487 - 494. [Abstract] [Full Text]

				E. A. Mellor, N. Frank, D. Soler, M. R. Hodge, J. M. Lora, K. F. Austen, and J. A. Boyce Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R PNAS, September 30, 2003; 100(20): 11589 - 11593. [Abstract] [Full Text] [PDF]

				S E A Attwood, C J Lewis, C S Bronder, C D Morris, G R Armstrong, and J Whittam Eosinophilic oesophagitis: a novel treatment using Montelukast Gut, February 1, 2003; 52(2): 181 - 185. [Abstract] [Full Text] [PDF]

				R.A. Baumgartner, G. Martinez, J.M. Edelman, G.G. Rodriguez Gomez, M. Bernstein, S. Bird, R. Angner, A. Polis, S.B. Dass, S. Lu, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone Eur. Respir. J., January 1, 2003; 21(1): 123 - 128. [Abstract] [Full Text] [PDF]

				K. Minoguchi, Y. Kohno, H. Minoguchi, N. Kihara, Y. Sano, H. Yasuhara, and M. Adachi Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast Chest, March 1, 2002; 121(3): 732 - 738. [Abstract] [Full Text] [PDF]

				S.-E. DAHLEN, K. MALMSTROM, E. NIZANKOWSKA, B. DAHLEN, P. KUNA, M. KOWALSKI, W. R. LUMRY, C. PICADO, D. D. STEVENSON, J. BOUSQUET, et al. Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 9 - 14. [Abstract] [Full Text] [PDF]

				J. E. Fish, E. Israel, J. J. Murray, A. Emmett, R. Boone, S. W. Yancey, and K. A. Rickard Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy Chest, August 1, 2001; 120(2): 423 - 430. [Abstract] [Full Text] [PDF]

				E. A. Mellor, A. Maekawa, K. F. Austen, and J. A. Boyce Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells PNAS, July 3, 2001; 98(14): 7964 - 7969. [Abstract] [Full Text] [PDF]

				S. S. Salvi, M. T. Krishna, A. P. Sampson, and S. T. Holgate The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma Chest, May 1, 2001; 119(5): 1533 - 1546. [Abstract] [Full Text] [PDF]

				H. Bisgaard Leukotriene Modifiers in Pediatric Asthma Management Pediatrics, February 1, 2001; 107(2): 381 - 390. [Abstract] [Full Text]

				O J Dempsey Leukotriene receptor antagonist therapy Postgrad. Med. J., December 1, 2000; 76(902): 767 - 773. [Abstract] [Full Text]

				N. C Barnes and C. J Miller Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials Thorax, June 1, 2000; 55(6): 478 - 483. [Abstract] [Full Text]

				L M KUITERT and N C BARNES Leukotriene receptor antagonists: useful in acute asthma? Thorax, April 1, 2000; 55(4): 255 - 256. [Full Text]

				R J Dockhorn, R A Baumgartner, J A Leff, M Noonan, K Vandormael, W Stricker, D E Weinland, and T F Reiss Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients Thorax, April 1, 2000; 55(4): 260 - 265. [Abstract] [Full Text]

				M. LAVIOLETTE, K. MALMSTROM, S. LU, P. CHERVINSKY, J.-C. PUJET, I. PESZEK, J. ZHANG, and T. F. REISS Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1862 - 1868. [Abstract] [Full Text]

				C.-G. Löfdahl, T. F Reiss, J. A Leff, E. Israel, M. J Noonan, A. F Finn, B. C Seidenberg, T. Capizzi, S. Kundu, and P. Godard Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients BMJ, July 10, 1999; 319(7202): 87 - 90. [Abstract] [Full Text]

				K. Malmstrom, G. Rodriguez-Gomez, J. Guerra, C. Villaran, A. Pineiro, L. X. Wei, B. C. Seidenberg, T. F. Reiss, and for the Montelukast/Beclomethasone Study Group* Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma: A Randomized, Controlled Trial Ann Intern Med, March 16, 1999; 130(6): 487 - 495. [Abstract] [Full Text] [PDF]

				J. M. Drazen, E. Israel, and P. M. O'Byrne Treatment of Asthma with Drugs Modifying the Leukotriene Pathway N. Engl. J. Med., January 21, 1999; 340(3): 197 - 206. [Full Text] [PDF]

				{blacktriangledown}Montelukast and {blacktriangledown}zafirlukast in asthma DTB, September 1, 1998; 36(9): 65 - 68. [Abstract] [Full Text] [PDF]

				T. F. Reiss, P. Chervinsky, R. J. Dockhorn, S. Shingo, B. Seidenberg, T. B. Edwards, and for the Montelukast Clinical Research Study Group Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma: A Multicenter, Randomized, Double-blind Trial Arch Intern Med, June 8, 1998; 158(11): 1213 - 1220. [Abstract] [Full Text] [PDF]